Pedro Pérez‐Segura

Large scale multifactorial likelihood quantitative analysis of <i>BRCA1</i> and <i>BRCA2</i> variants: An ENIGMA resource to support clinical variant classification

Michael T. Parsons, Emma Tudini, Hongyan Li et al. · Human Mutation · 2019 · 148 citations · Full text

Genetics, Genetic Epidemiology, Pathology +25

Phase II trial of dacomitinib, a pan–human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification

Juan Manuel Sepúlveda-Sánchez, María Ángeles Vaz Salgado, Carmen Balañá et al. · Neuro-Oncology · 2017 · 119 citations · Full text

A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)

Carmen Balañá, María Ángeles Vaz Salgado, Juan Manuel Sepúlveda-Sánchez et al. · Neuro-Oncology · 2020 · 103 citations · Full text

Association between <i>BRCA1</i> and <i>BRCA2</i> mutations and cancer phenotype in Spanish breast/ovarian cancer families: Implications for genetic testing

Miguel de la Hoya, Ana Osório, Sara Sulleiro et al. · International Journal of Cancer · 2001 · 73 citations

Genomic Signatures of Immune Activation Predict Outcome in Advanced Stages of Ovarian Cancer and Basal-Like Breast Tumors

Ana Alcaráz-Sanabria, Mariona Baliu‐Piqué, Cristina Sáiz-Ladera et al. · Frontiers in Oncology · 2020 · 60 citations · Full text